How do I hire a part-time CRO for a medical device company in 2027?

What a part-time CRO is, and what the alternatives actually are

A part-time or fractional CRO is a senior revenue executive who works for you a defined number of days per month — typically four to eight, or roughly 10 to 20 days per quarter — under a retainer rather than a salary. They own revenue strategy: segmentation, pricing posture, channel design, the sales process itself, the hiring plan for the first reps, and personal involvement in a handful of the accounts that decide whether your year works. They do not run daily standups, they do not chase every deal, and they are not a substitute for a rep carrying a bag.

For a medical device company, the practical alternatives cluster into five options, and it is worth being blunt about what each one buys.

A full-time CRO. Total compensation plus benefits, equity, and a search that realistically takes three to six months to close. You get 40-plus hours per week, daily pipeline management, forecast ownership, and someone accountable for team culture. Below roughly 10M ARR with one to three salespeople, most device companies cannot generate enough executive-scale work to keep a full-time CRO usefully busy, and the hire eats runway that should be funding clinical evidence or regulatory work.

A full-time VP of Sales. Cheaper than a CRO, more hands-on, and frequently the better hire when your problem is execution rather than strategy. A VP of Sales will run the reps, sit in on calls, and manage the number week to week. What they usually will not do is redesign your channel strategy, negotiate your first GPO relationship, or tell you that your pricing model is incompatible with hospital capital budget cycles.

A fractional sales consultant. A meaningful step down in seniority and cost from a fractional CRO — often two to four days a month, focused on pitch coaching, CRM hygiene, call reviews, and basic process design. Genuinely useful pre-revenue. What you lose is the ability to make structural decisions: a consultant will improve how you sell what you sell; they will not credibly tell your board that the direct model is wrong and you should be selling through distributors.

An advisor or board member with device experience. Low cash cost, often equity-only, a few hours a month. Excellent for introductions and pattern-matching, useless for anything requiring sustained execution. Advisors give you opinions; a fractional CRO gives you artifacts — a documented sales process, a territory model, a compensation plan, a hiring scorecard.

Founder-led sales with no leadership hire. Do not dismiss this. If you have fewer than about fifteen active opportunities and your founder is technically credible with clinicians, founder-led selling often outperforms an early leadership hire, because in device sales the buyer frequently wants the person who designed the thing in the room. The failure mode is that founder-led sales does not scale and does not document itself, so when you finally hire, there is no playbook to hand over.

The honest comparison: a fractional CRO occupies a narrow but real band. You want one when the strategy is genuinely unresolved, the sales motion is complicated enough that getting it wrong costs you a year, and you do not have the revenue to defend a full-time executive salary. That describes a lot of device companies between first commercial revenue and roughly 10M ARR.

How to choose between them without guessing

Start with three diagnostic questions, in order, because the answer to each one eliminates options.

Is your problem strategy or execution? Write down the single reason revenue is not where you want it. If the answer sounds like "we do not know which channel to build" or "our pricing does not survive a value analysis committee" or "we cannot tell whether to sell to the surgeon or the supply chain director," that is a strategy problem and a fractional CRO is the right shape. If the answer sounds like "we have twelve opportunities and nobody is working them consistently," that is execution, and you want a VP of Sales, a sales manager, or frankly another rep — a fractional CRO will diagnose the same thing in week three and charge you for the privilege.

How much executive-grade work actually exists per month? Count it honestly. Sales process design, comp plan build, channel negotiation, and coaching two reps is comfortably six to eight days a month for a quarter or two, then drops. If your honest count is under three days a month, you want an advisor. If it is consistently over twelve, you are paying fractional rates for near-full-time work and should hire full-time.

What does your regulatory timeline do to your revenue timeline? A 510(k) path with a predicate device and a clear pathway means commercial revenue is a near-term, addressable problem. A PMA path or an IDE trial means your revenue timeline is long and partly outside your control — you want strategy and market preparation, not a sales leader burning retainer while you wait for clearance. In that case, a fractional CRO engaged at four days a month to build the go-to-market and reimbursement narrative is far better value than a full-time hire idling.

Layer stage on top of those answers. Pre-revenue: advisor or a light fractional engagement, four days a month. Sub-2M ARR with a working product and early accounts: fractional CRO, four to six days a month, is the sweet spot. 2M to 10M ARR with two or three reps: fractional CRO at six to eight days a month, often paired with a full-time sales manager who handles daily execution. Above roughly 10M ARR with five-plus salespeople: hire full-time. The fractional model breaks down when the volume of daily decisions exceeds what someone can carry across a gap of several days.

Two more filters worth applying before you commit. First, ask whether the work you need is transferable. A fractional CRO who builds a process, documents it, and trains your team leaves behind an asset. One who personally closes three deals and departs leaves you exactly where you started with a smaller bank balance — so weight scope toward things that persist. Second, ask who this person reports to and who they can direct. A fractional executive with no authority over your reps is a very expensive consultant. Write the reporting line into the agreement.

Costs, timelines, and what impact to expect

Cash retainers for fractional revenue leadership vary widely, and the honest answer is that the range is wide enough that any single number quoted to you should be interrogated. The drivers, roughly in order of impact:

Specificity of the sales motion. This matters more than geography. Capital equipment sold to hospitals — six-figure purchases, capital budget cycles, value analysis committee review, multi-stakeholder approval — requires a fundamentally different playbook than consumables moving through a distributor network at per-unit economics, and that is different again from a device billed under a reimbursement code where your real sales problem is payer coverage. A CRO who has personally run the exact motion you need commands a premium, and it is usually worth paying, because the alternative is funding their education.

Days per month. Most engagements land at four to eight days. Retainers scale close to linearly with days, though not perfectly — the first two days a month carry fixed overhead of context-switching and are effectively more expensive per day than days five through eight.

Seniority and track record. Someone who has scaled a device company through an FDA cycle and into hospital procurement prices differently than someone building their first consulting practice. Both can be the right hire; they are the right hire for different stages.

Equity. Fractional CROs at early-stage companies commonly take equity in exchange for a cash discount, typically in the range of 0.5% to 2%, structured as options on a standard four-year vest with a one-year cliff. Only offer equity if the cash is genuinely discounted against what the person would otherwise command — equity on top of full-rate cash is a bad trade for you and signals inexperience.

Travel and expenses. Budget these separately and explicitly. Device sales involves trade shows, on-site hospital meetings, distributor visits, and surgeon dinners. An engagement that looks affordable on retainer alone can add meaningfully in travel across a quarter. Cap it, or agree a per-trip approval threshold.

On timelines: expect two to six weeks from starting your search to a signed agreement if you already know the profile you want, considerably longer if you are still figuring that out. Onboarding a fractional executive into a device company takes longer than into a software company, because they need to understand your regulatory status, your clinical evidence, your reimbursement situation, and your quality system constraints on what sales can and cannot say. Give them two to three weeks of ramp before expecting output, and give them your 510(k) or PMA documentation, your instructions for use, and your current claims matrix on day one — a good CRO will ask for these unprompted, and one who does not is a warning sign.

On impact: in the first 90 days, realistic outcomes are a documented sales process, a cleaned and honestly staged pipeline, a defined ideal customer profile with named target accounts, participation in a handful of live customer conversations, and a hiring plan. Revenue impact inside 90 days is unlikely and you should be suspicious of anyone promising it — device sales cycles frequently run six to eighteen months from first contact to purchase order, so a CRO who starts in January is influencing deals that close in the second half of the year at the earliest. Measure the first quarter on process and pipeline quality, not on bookings. Measure the second and third quarters on pipeline conversion and cycle time. Measure the fourth on revenue.

What good looks like at the one-year mark: a repeatable process a new rep can be trained into, a channel decision made and executed rather than deferred, at least one structural commercial relationship established (a distributor agreement, a GPO contract, an IDN relationship), and a sales team that exists and is producing. If a year has passed and none of those exist, the engagement failed regardless of how good the meetings felt.

Vetting, contracting, and the handoff that decides whether it worked

Vetting a fractional CRO for a medical device company means going well past generic sales-leadership questions. Three areas carry disproportionate signal.

Regulatory and compliance fluency. Ask what they did when a rep made a claim outside the cleared indications. Ask how they handled adverse event reporting flowing back through the sales organization. Ask about ISO 13485 quality system constraints on sales collateral and about what happens to sales activity during an FDA inspection. Someone who has lived this will answer immediately and with irritation in their voice, because it has cost them deals. Someone who has not will speak abstractly about "compliance being important."

Channel and GPO experience. Ask for a specific example of structuring a distributor agreement — territory, exclusivity, margin, minimums, termination. Ask them to walk through a GPO contract negotiation. If they cannot name real organizations in the space — Vizient, Premier, HealthTrust — and describe how contracting actually works with them, be cautious. Ask, too, about integrated delivery networks and about how they handled the difference between winning a contract and driving pull-through once it exists, which is the mistake device companies make most often.

Clinical and economic value selling. Surgeons buy on clinical outcomes; administrators buy on total cost. Ask what a clinical evidence dossier they built contained. Ask them to describe a cost-per-procedure analysis they used in a deal. Ask how they prepared a team for a value analysis committee presentation — who attends, what they ask, what kills a submission. This last question is the single best filter in the interview; if there is no concrete example, the regulated-market fluency is not there.

Beyond those, run standard reference discipline: two references from founders or CEOs they worked for fractionally, one from someone they hired or managed, and one from a customer if you can get it. Ask every reference the same closing question — what did they leave behind that is still in use? That answer separates operators from advisors.

On contracting, keep it simple and reversible. Month-to-month or quarterly, with a 30-day termination right on both sides. Write in the days per month, what counts as a day, how travel is billed and capped, who they can direct, what systems and data they get access to, and — critically for a device company — a confidentiality clause that covers clinical and regulatory material, plus a conflicts clause preventing them from taking a competing device engagement during the term and for a defined period after. Also address IP explicitly: process documentation, comp plans, and territory models built during the engagement should belong to you, not travel with them to the next client.

Structure the first 90 days on three milestones. By day 30: a pipeline audit and a proposed sales process, adapted from a real framework — a MEDDIC variant works well in device because it forces identification of the economic buyer and the champion, both of which are non-obvious in hospital selling. By day 60: participation in at least three to five live customer calls or meetings, either coaching your people or directly advancing a deal, plus a channel recommendation. By day 90: a hiring plan for your first full-time salesperson if you need one, or a documented coaching cadence for founder-led selling if you do not. Miss the milestones, exit with minimal damage. Exceed them, renew or expand.

The handoff is where fractional engagements most often waste money, so design for it from the start. Every engagement should produce artifacts that survive the person: the written sales process with stage definitions and exit criteria, the ICP and target account list with rationale, the compensation plan, the pricing and discount authority matrix, the objection handling and VAC preparation material, and a documented state of every commercial relationship — which distributor, which GPO, which IDN, who the contact is, where it stands. Require these as deliverables in the agreement rather than hoping they materialize. Store them in your own systems, in your own CRM and drive, from day one, not on the CRO's laptop.

Plan the transition before you need it. A fractional CRO engagement should have a stated endgame: either it converts to full-time, or it hands off to a VP of Sales you hire with the CRO's help, or it winds down to advisory as the founder resumes ownership. Say which one you are aiming at in the first month, and revisit it quarterly. The worst outcome is drift — an engagement that runs eighteen months without anyone asking whether it should still exist, and a RevOps function that never got built because the fractional leader was doing the thinking that should have been institutionalized.

Where to actually find candidates

Fractional executive supply is not evenly distributed, and the general marketplaces will hand you a hundred generalists for every one person who has sold a Class II device into a health system. Search narrow.

Executive and revenue-leader communities are the highest-yield starting point — Pavilion and RevOps Co-op both host senior revenue people, many of whom run fractional practices, and both let you post a specific ask rather than browsing profiles. LinkedIn works if you search by what people did rather than what they call themselves: search for former VP Sales and CRO titles at device companies of roughly your size and stage, then filter for people whose current role reads as advisory, consulting, or fractional. Medical device trade associations and regional cluster organizations — the Minneapolis, Boston, Orange County, and Bay Area device corridors all have them — surface people already inside the industry network.

Your investors and board are an underused channel. If you are venture- or strategic-backed, your investors have almost certainly placed fractional leadership at other portfolio companies and can tell you who performed. Ask specifically for someone who worked out, not for a list. Similarly, your existing distributors and even your customers know who the strong commercial operators in the category are.

Do not over-index on geography. Remote fractional engagement is entirely standard now, with travel for key customer meetings, trade shows, and quarterly on-site work. A candidate three time zones away with direct hospital capital equipment experience beats a local candidate whose background is B2B software, every time. What you should insist on is that they will travel — device selling has irreducible in-person components, and a fractional CRO who has never met your surgeon champion cannot help you keep them.

One last filter, and it is the cheapest one available: ask each finalist to spend an hour reviewing your pipeline and telling you what they see. The good ones will come back with two or three specific, uncomfortable observations. The rest will come back with a framework.

Related questions

Can a fractional CRO help before we have FDA clearance?

Yes, and it is often the best-value window. Pre-clearance work is market sizing, ICP definition, reimbursement strategy, KOL relationship building, and distributor conversations — all of which take months and can run in parallel with the regulatory process. Scope it at three to four days monthly.

Should the fractional CRO or the founder own the GPO relationship?

The founder or CEO should own the relationship; the CRO should architect and run the process. GPOs and health systems value continuity, and a contact who disappears when a contract ends damages trust. Have the CRO build it and introduce you into it deliberately.

How is this different from hiring a fractional CRO for a software company?

The sales motion is the difference. Device selling adds regulatory constraints on claims, clinical evidence requirements, value analysis committee gatekeeping, GPO and IDN contracting, and sales cycles measured in quarters rather than weeks. A software-only background means learning all of that on your retainer.

What if our sales problem is really a product or reimbursement problem?

A good fractional CRO will tell you that in the first month, which is itself worth the money. If coverage or coding is the blocker, you need a reimbursement consultant, not a revenue leader — though the CRO can help define what commercial evidence the payer conversation requires.

Do we need RevOps in place before hiring a fractional CRO?

No, but expect it to be an early deliverable. Most sub-10M device companies have a CRM nobody trusts. Fixing data hygiene, stage definitions, and basic reporting is usually the first thing a competent fractional leader does, because nothing else is measurable without it.

FAQ

How many days per month should a part-time CRO work for a device company?

Four to eight days per month covers most situations. Four is right pre-revenue or when the scope is strategic only. Six to eight fits a company with early commercial revenue, a small team to coach, and active channel decisions. Above twelve days consistently, you are paying fractional rates for near-full-time work and should hire full-time instead.

What should I pay, and how do I know if a quote is fair?

Retainers scale with days, seniority, and how specifically the person's background matches your motion. Rather than anchoring on a number, ask two or three candidates to quote against an identical written scope — same days, same deliverables, same travel expectations — and the spread will tell you what the market is for your particular ask.

Is equity normal, and how much?

It is common at early stage, typically 0.5% to 2%, on a standard four-year vest with a one-year cliff. Grant it only against a genuine cash discount. If someone wants full market cash plus equity, they are treating you as a client and an investment simultaneously, which misaligns the incentive.

Can a fractional CRO work remotely?

Yes — remote is the default, with travel for customer meetings, trade shows, distributor visits, and quarterly on-sites. Confirm they are experienced with remote pipeline reviews and virtual deal coaching, and write the expected travel cadence into the agreement so it is not renegotiated in month three.

What if we cannot afford a fractional CRO retainer at all?

Step down the ladder rather than compromising on quality. A fractional sales consultant at two to four days monthly can handle process design and pitch coaching. An advisor with device experience costs little and gives you introductions. Both are better than hiring an underqualified CRO because the title was affordable.

How do we know the engagement is working?

Judge the first quarter on artifacts and pipeline quality — documented process, honest staging, defined ICP, named target accounts. Judge later quarters on conversion rate and cycle time. Do not judge the first 90 days on bookings; device cycles are too long for that to mean anything either way.

Sources

• U.S. Food and Drug Administration — Device Advice
• FDA — 510(k) Premarket Notification
• ISO 13485 — Medical devices quality management systems
• Vizient
• Premier Inc.
• AdvaMed
• Harvard Business Review
• Pavilion
• First Round Review
• SaaStr

Related on PULSE

• [How do I find a fractional CRO in Millsboro in 2027?](/knowledge/tl20032)
• [How do I hire a fractional CRO in Tulsa in 2027?](/knowledge/tl9705)
• [How do I find a fractional CRO in Oakton in 2027?](/knowledge/tl14291)
• [Where do I find an interim CRO in Durham in 2027?](/knowledge/tl15485)
• [How do I find a fractional CRO in Montgomery Village in 2027?](/knowledge/tl19472)
• [How do I hire a fractional CRO in Charlotte in 2027?](/knowledge/tl9627)